103 related articles for article (PubMed ID: 16875457)
1. A fine pile of paté: the cautionary tale of telithromycin, hepatic failure, and study 3014.
Barie PS
Surg Infect (Larchmt); 2006 Jun; 7(3):247-9. PubMed ID: 16875457
[No Abstract] [Full Text] [Related]
2. Telithromycin and acute liver failure.
Graham DJ
N Engl J Med; 2006 Nov; 355(21):2260-1. PubMed ID: 17124030
[No Abstract] [Full Text] [Related]
3. The FDA and the case of Ketek.
Ross DB
N Engl J Med; 2007 Apr; 356(16):1601-4. PubMed ID: 17442902
[No Abstract] [Full Text] [Related]
4. Fraud, errors taint a key study of widely used Sanofi drug; despite some faked results, FDA approves antibiotic; one doctor's cocaine use; company defends safety.
Mathews AW
Wall St J (East Ed); 2006 May; ():A1, A12. PubMed ID: 16838449
[No Abstract] [Full Text] [Related]
5. Ketek--the FDA perspective.
Soreth J; Cox E; Kweder S; Jenkins J; Galson S
N Engl J Med; 2007 Apr; 356(16):1675-6. PubMed ID: 17442912
[No Abstract] [Full Text] [Related]
6. Telithromycin: QT prolongation.
Prescrire Int; 2007 Apr; 16(88):71. PubMed ID: 17465034
[No Abstract] [Full Text] [Related]
7. Telithromycin and the FDA: implications for the future.
Shlaes DM; Moellering RC
Lancet Infect Dis; 2008 Feb; 8(2):83-5. PubMed ID: 18222155
[No Abstract] [Full Text] [Related]
8. Risk of hepatotoxicity associated with the use of telithromycin: a signal detection using data mining algorithms.
Chen Y; Guo JJ; Healy DP; Lin X; Patel NC
Ann Pharmacother; 2008 Dec; 42(12):1791-6. PubMed ID: 19033479
[TBL] [Abstract][Full Text] [Related]
9. Telithromycin-associated hepatotoxicity: Clinical spectrum and causality assessment of 42 cases.
Brinker AD; Wassel RT; Lyndly J; Serrano J; Avigan M; Lee WM; Seeff LB
Hepatology; 2009 Jan; 49(1):250-7. PubMed ID: 19085949
[TBL] [Abstract][Full Text] [Related]
10. Understanding the regulatory hurdles for antibacterial drug development in the post-Ketek world.
Echols RM
Ann N Y Acad Sci; 2011 Dec; 1241():153-61. PubMed ID: 22191531
[TBL] [Abstract][Full Text] [Related]
11. Telithromycin: visual disorders, myasthenia. Case fatalities: this macrolide has a negative risk-benefit balance; its use not justified.
Prescrire Int; 2008 Apr; 17(94):66. PubMed ID: 18516818
[No Abstract] [Full Text] [Related]
12. Telithromycin: visual disorders.
Prescrire Int; 2010 Apr; 19(106):71. PubMed ID: 20568490
[TBL] [Abstract][Full Text] [Related]
13. Acute hepatitis attack after exposure to telithromycin.
Onur O; Guneysel O; Denizbasi A; Celikel C
Clin Ther; 2007 Aug; 29(8):1725-9. PubMed ID: 17919553
[TBL] [Abstract][Full Text] [Related]
14. Telithromycin: severe hepatitis.
Prescrire Int; 2006 Aug; 15(84):139. PubMed ID: 16991219
[No Abstract] [Full Text] [Related]
15. Effective integration of medical and pharmacy claims to better protect patient safety--a long road yet to travel.
Curtiss FR
J Manag Care Pharm; 2007 Jun; 13(5):429-30. PubMed ID: 17605515
[No Abstract] [Full Text] [Related]
16. Telithromycin.
Turner M; Corey GR; Abrutyn E
Ann Intern Med; 2006 Mar; 144(6):447-8. PubMed ID: 16549859
[No Abstract] [Full Text] [Related]
17. Telithromycin and myasthenic crisis.
Jennett AM; Bali D; Jasti P; Shah B; Browning LA
Clin Infect Dis; 2006 Dec; 43(12):1621-2. PubMed ID: 17109301
[No Abstract] [Full Text] [Related]
18. Severe hepatotoxicity of telithromycin.
Bertino JS
Ann Intern Med; 2006 Sep; 145(6):472; author reply 472. PubMed ID: 16983140
[No Abstract] [Full Text] [Related]
19. Telithromycin use and spontaneous reports of hepatotoxicity.
Dore DD; DiBello JR; Lapane KL
Drug Saf; 2007; 30(8):697-703. PubMed ID: 17696582
[TBL] [Abstract][Full Text] [Related]
20. Telithromycin: another interacting macrolide.
Prescrire Int; 2005 Oct; 14(79):179. PubMed ID: 16287219
[No Abstract] [Full Text] [Related]
[Next] [New Search]
